Last reviewed · How we verify
Pomegrante and Ginkgo biloba group — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Pomegrante and Ginkgo biloba group (Pomegrante and Ginkgo biloba group) — Ahmed A. H. Abdellatif.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pomegrante and Ginkgo biloba group TARGET | Pomegrante and Ginkgo biloba group | Ahmed A. H. Abdellatif | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pomegrante and Ginkgo biloba group CI watch — RSS
- Pomegrante and Ginkgo biloba group CI watch — Atom
- Pomegrante and Ginkgo biloba group CI watch — JSON
- Pomegrante and Ginkgo biloba group alone — RSS
Cite this brief
Drug Landscape (2026). Pomegrante and Ginkgo biloba group — Competitive Intelligence Brief. https://druglandscape.com/ci/pomegrante-and-ginkgo-biloba-group. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab